CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stallergenes SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stallergenes SA
7 Alexis de Tocqueville Street
Phone: +33 155592310p:+33 155592310 Antony, 92160  France Ticker: GENPGENP
On 9/8/2015, Stallergenes SA and Greer Laboratories, both subsidiaries of Ares Allergy Holdings Plc, merged to form a combined company that will operate as Stallergenes Greer Plc.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Stallergenes SA is a France-based biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. It has developed a range of in vivo and in vitro tests for use in the medical profession. The Company's range of products includes more than 150 references. The Company also has research and development teams divided between clinical development, laboratory research and development of candidate products, and regulatory affairs. Stallergenes SA is present in almost 40 countries via ten subsidiaries in in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain and Canada, among others. It has entered into numerous partnerships and distribution agreements.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201412/31/2014Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board PatrickLanglois 7/1/2012 5/27/2011
Chief Executive Officer, Director ChristianChavy 66 3/31/2014 11/10/2010
Deputy Chief Executive Officer, Chief Pharmacist and Director LaurentArtaud 3/5/2014 1/1/2007
4 additional Officers and Directors records available in full report.

Business Names
Business Name
0P16
5S6
ALERGO PHARMA S.R.L
GENP
Stallergenes Greer Plc
Stallergenes S.A.

General Information
Number of Employees: 1,040 (As of 12/31/2014)
Outstanding Shares: 13,864,433 (As of 12/31/2014)
Shareholders: 9,021
Stock Exchange: EPA
Fax Number: +33 155592068


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023